Pregnancy Fetal Medicine

Embryotoxicity of a single dose of medroxyprogesterone acetate (MPA) and maternal serum MPA concentrations in cynomolgus monkey (Macaca fascicularis)

Prahalada S, Carroad E, Cukierski M, Hendrickx AG

Published December 1985 Teratology, 32(3), 421-432
DOI 10.1002/tera.1420320312 PMID 2934853

RRM Academy Synopsis

Depo-Provera in early pregnancy altered monkey infants' genitalia

Monkey infants of both sexes had abnormal external genitalia after one early-pregnancy Depo-Provera injection, a 1985 experiment in 12 pregnant cynomolgus monkeys found. Each monkey got one injection at one of two dose levels. The high-dose infants also had smaller adrenal glands than controls.

Study at a glance, 12 pregnant cynomolgus monkeys: Early-pregnancy Depo-Provera altered monkey infants' genitalia
Study at a glance, 12 pregnant cynomolgus monkeys: Early-pregnancy Depo-Provera altered monkey infants' genitalia. Source: Prahalada S et al., 1985, PMID 2934853.

Key Findings

  • In the low-dose group, all 3 female infants had fused labia (partial in 2, complete in 1), a prominent median raphe, and an enlarged clitoris.
  • Each female infant in the high-dose group had complete labial fusion and a distinct penile urethra. Anogenital distance was significantly greater in treated females than in control females (P < 0.001).
  • Male infants in both dose groups had a shortened penis and less conspicuous or absent scrotal swelling. One male in each group had hypospadias. Male anogenital distance was similar to controls.
  • Adrenal glands were significantly smaller than in controls in the high-dose group (P < 0.05) and not significantly smaller in the low-dose group.
  • Measurable MPA was present in cord blood from the five infants tested, in both dose groups.

Interpretation

Researchers gave 12 pregnant cynomolgus monkeys one injection each, six per dose group, and examined the infants at term. Historical records of untreated monkeys housed the same way served as the comparison group. Doses were multiples of the human contraceptive dose. Three of 12 treated monkeys aborted (25%), close to the 22.5% rate among untreated, indoor-housed monkeys in the colony. One low-dose infant had a ventricular septal defect of unclear significance. The authors conclude that one injection in early pregnancy causes selective embryotoxicity in cynomolgus monkeys. They state that the exact mechanism behind the genital changes is unknown.

RRM Context

Depo-Provera is a synthetic progestin that suppresses the cycle. RRM works with ovulation and the progesterone that follows it. The authors note that human female infants can develop masculinized genitalia when mothers take male hormones or synthetic progestins. The authors advise routine pregnancy diagnosis, so that women avoid exposure early in pregnancy.

Abstract

A single dose of MPA (Depo-Provera; Upjohn Co., Kalamazoo, Michigan) was administered intramuscularly to 12 time-mated pregnant cynomolgus monkeys on day 27 (+/- 2) of gestation at 25 mg/kg or at 100 mg/kg. Maternal blood samples were collected immediately prior to MPA injection and then at regular intervals until cesarean section at term (day 152 +/- 3). Infants in both dose groups had external genital abnormalities. Female infants in the low-dose groups had partial or complete labial fusion, prominent median raphe, and clitoral hypertrophy; at high doses (100 mg/kg), the female infants had complete labial fusion and a distinct penile urethra. MPA had an opposite effect on external genitalia of male infants. The penis was short and the scrotal swelling was absent or less conspicuous, and two males had hypospadias. The adrenal glands were significantly smaller (P less than 0.05) in infants of both sexes treated with 100 mg/kg. One of the infants treated with 25 mg/kg of MPA had a muscular ventricular septal defect. Serum concentrations of MPA were determined by radioimmunoassay in eight pregnant monkeys. In the 25 mg/kg group the patterns of MPA profiles in the serum were similar in all four animals. An initial peak occurred at 24-48 hr postinjection (2.7-9.6 ng/ml), followed by a slight decrease at 3 days postinjection (gestational day 30), and then a steady increase to maximum levels of 10-14 ng/ml occurring between gestational days 37 and 50. Serum levels gradually declined to concentrations below 5 ng/ml by midgestation in three of four monkeys. By comparison, both the patterns and magnitude of MPA concentration showed great interanimal variation in the 100 mg/kg group. MPA was present in cord blood at measurable concentrations in infants at both dose groups; the levels ranged from 0.6 to 8.3 ng/ml, corresponding to 40-72% of the maternal concentrations. These results demonstrate that a single injection of MPA during early pregnancy causes selective embryotoxicity in both male and female fetuses. Presence of high levels of MPA in maternal sera during the critical period of genital development can cause specific genital defects; however, the exact mechanism by which MPA causes these paradoxical genital abnormalities is unknown.

Topics

By this author

Related research

Pregnancy › Fetal Medicine › Congenital Anomalies
PMID 2934853 2934853 DOI 10.1002/tera.1420320312 10.1002/tera.1420320312 Prahalada et al. 1985, Prahalada 1985